elritercept, Placebo to match ker-050 solution for injection
KER-050-D301
Phase 3 small_molecule active
Quick answer
elritercept, Placebo to match ker-050 solution for injection for myelodysplastic neoplasms/syndromes (MDS) is a Phase 3 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- myelodysplastic neoplasms/syndromes (MDS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active